Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

ICU TopicsPharmacology

ICU · Pharmacology

Antibiotic pharmacokinetics in critical illness

Also known as Antibiotic dosing in ICU · Augmented renal clearance (ARC) · Volume of distribution in sepsis · Beta-lactam therapeutic drug monitoring

Critical illness alters antibiotic pharmacokinetics (PK), often leading to sub-therapeutic levels and treatment failure. Key changes: (1) Increased volume of distribution (Vd) — capillary leak, fluid resuscitation, hypoalbuminaemia dilute water-soluble drugs (beta-lactams, aminoglycosides). (2) Augmented renal clearance (ARC) — young trauma/sepsis patients have increased renal blood flow → enhanced clearance of renally eliminated drugs → sub-therapeutic levels. (3) Organ failure — renal/hepatic impairment reduces clearance → accumulation → toxicity. (4) CRRT — removes drugs, need dose adjustment. (5) ECMO — sequesters drugs in circuit, increases Vd. Principles: give LOADING DOSE for severe infections (especially beta-lactams — target 4-5x MIC). Consider extended/continuous infusion for beta-lactams (time-dependent killing). Monitor levels (TDM) for vancomycin, aminoglycosides, beta-lactams.

medium24 referencesUpdated 26 July 202620 min readSource-verified · Oct 2026

Checked against its sources on 1 Oct 2026

Practise this topic

  • 8 MCQs

Your progress

Saved on this device.

Practise this topic8 MCQs with explanations

Target exams

CICMFFICMEDIC

Red flags

  • Standard doses may be sub-therapeutic in ICU patients — consider loading doses + extended infusion
  • Augmented renal clearance (ARC) in young trauma/sepsis patients — increased dose needed
  • Beta-lactams: time above MIC is the PK/PD target — use extended/continuous infusion for severe infections
  • Vancomycin: trough 15-20 mg/L for severe MRSA infections. AUC/MIC target 400-600
On this page
Study tools

Your progress

Saved on this device.

Practise this topic8 MCQs with explanations

Target exams

CICMFFICMEDIC

Red flags

  • Standard doses may be sub-therapeutic in ICU patients — consider loading doses + extended infusion
  • Augmented renal clearance (ARC) in young trauma/sepsis patients — increased dose needed
  • Beta-lactams: time above MIC is the PK/PD target — use extended/continuous infusion for severe infections
  • Vancomycin: trough 15-20 mg/L for severe MRSA infections. AUC/MIC target 400-600
The one-line answer

Critical illness breaks every assumption baked into the standard antibiotic dose. The volume of distribution balloons (capillary leak, fluids, hypoalbuminaemia), augmented renal clearance strips out the renally-cleared drugs, and CRRT and ECMO each demand their own maths. Load for the volume, time the beta-lactam, chase the AUC — beta-lactams run on time above MIC, vancomycin on AUC 400–600, aminoglycosides on a once-daily peak. Use TDM, because in the ICU a standard dose is a guess, not a prescription.

[1]

Meet the patient

A 23-year-old motorcyclist arrives in septic shock from an open femur fracture and a contaminated wound. You start piperacillin-tazobactam 4.5 g q6h and noradrenaline, and source-control the leg. By day 3 the lactate is stuck at 3.2, the fever swings every shift, the cultures are negative — and your registrar asks whether to escalate to meropenem.[2][3][10]

Before you broaden the spectrum, measure what the kidney is doing. A 4-hour urinary creatinine clearance comes back at 150 mL/min. That is augmented renal clearance, and it is washing your beta-lactam out faster than the dosing interval can replace it — the drug is failing the patient, not the bug. The question this whole topic answers: which PK derangement is failing him, and what do you change?[2][3][24]

ICU Fellowship (CICM) Pro

Continue reading

You have read the opening of this topic. The complete unit — every section and its primary-source references — is part of the ICU Fellowship (CICM) fellowship library.

Sign in to continueSee pricing
References24ShowHide
  1. [1]Roberts JA, Abdul-Aziz MH, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions Lancet Infect Dis, 2014.PMID 24768475
  2. [2]Udy AA, Roberts JA, et al. Implications of augmented renal clearance in critically ill patients Nat Rev Nephrol, 2011.PMID 21769107
  3. [3]Roberts JA, Paul SK, et al. DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis, 2014.PMID 24429437
  4. [4]Dulhunty JM, Roberts JA, et al. A Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis Am J Respir Crit Care Med, 2015.PMID 26200166
  5. [5]Dulhunty JM, Brett SJ, et al. Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With Sepsis: The BLING III Randomized Clinical Trial JAMA, 2024.PMID 38864155
  6. [6]Rybak MJ, Le J, et al. Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists Pharmacotherapy, 2020.PMID 32227354
  7. [7]Pagkalis S, Mantadakis E, et al. Pharmacological considerations for the proper clinical use of aminoglycosides Drugs, 2011.PMID 22085385
  8. [8]Vardakas KZ, Voulgaris GL, et al. Prolonged versus short-term intravenous infusion of antipseudomonal β-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials Lancet Infect Dis, 2018.PMID 29102324
  9. [9]Roberts JA, Bellomo R, et al. Machines that help machines to help patients: optimising antimicrobial dosing in patients receiving extracorporeal membrane oxygenation and renal replacement therapy using dosing software Intensive Care Med, 2022.PMID 35997793
  10. [10]Harris PNA, Tambyah PA, et al. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial JAMA, 2018.PMID 30208454
  11. [11]Dulhunty JM, Roberts JA, et al. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial Clin Infect Dis, 2013.PMID 23074313
  12. [12]Rybak MJ, Lomaestro BM, et al. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists Pharmacotherapy, 2009.PMID 19873687
  13. [13]Nicolau DP, Freeman CD, et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients Antimicrob Agents Chemother, 1995.PMID 7793867
  14. [14]Beumier M, Casu GS, et al. β-lactam antibiotic concentrations during continuous renal replacement therapy Crit Care, 2014.PMID 24886826
  15. [15]Choi G, Gomersall CD, et al. Principles of antibacterial dosing in continuous renal replacement therapy Crit Care Med, 2009.PMID 19487930
  16. [16]Shaw AR, Chaijamorn W, Mueller BA We Underdose Antibiotics in Patients on CRRT Semin Dial, 2016.PMID 27082510
  17. [17]Srour N, Lopez C, et al. Vancomycin dosing in high-intensity continuous renal replacement therapy: A retrospective cohort study Pharmacotherapy, 2023.PMID 37458062
  18. [18]Hefny F, Stuart A, et al. Prevalence and Risk Factors of Augmented Renal Clearance: A Systematic Review and Meta-Analysis Pharmaceutics, 2022.PMID 35214177
  19. [19]Maan G, Keitoku K, et al. Cefepime-induced neurotoxicity: systematic review J Antimicrob Chemother, 2022.PMID 35971666
  20. [20]Chen XY, Xu RX, et al. Acute kidney injury associated with concomitant vancomycin and piperacillin/tazobactam administration: a systematic review and meta-analysis Int Urol Nephrol, 2018.PMID 29752626
  21. [21]Williams PG, Tabah A, Cotta MO, et al. International survey of antibiotic dosing and monitoring in adult intensive care units Crit Care, 2023.PMID 37331935
  22. [22]Hagel S, Bach F, et al. Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial Intensive Care Med, 2022.PMID 35106617
  23. [23]Märtson AG, Barber KE, et al. The pharmacokinetics of antibiotics in patients with obesity: a systematic review and consensus guidelines for dose adjustments Lancet Infect Dis, 2025.PMID 40383125
  24. [24]Bilbao-Meseguer I, Rodríguez-Gascón A, et al. Augmented Renal Clearance in Critically Ill Patients: A Systematic Review Clin Pharmacokinet, 2018.PMID 29441476

Test yourself

Practise what you just read

  • 8 MCQs
ICU Fellowship (CICM) Pro

$29/ monthor $279 / year

The complete ICU Fellowship (CICM) library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousAntiarrhythmics — Vaughan-Williams ClassificationPharmacologyNextAnticoagulants & Antithrombotics — PharmacologyPharmacology